Background: The combination of cyclophosphamide (CY) and antithymocyte globulin (ATG) has been used as a standard conditioning regimen for matched related donor transplantation in patients with severe aplastic anemia.
A cquired severe aplastic anemia (SAA) is a rare, lifethreatening disease characterized by bone marrow failure. 1 Hematopoietic stem cell transplantation (HSCT) is the standard therapeutic approach for patients with SAA when a matched related donor is available. The overall outcome of matched sibling transplantation in pediatric patients is superior to that in adult patients, with an overall 5-year survival of 82% with transplant-related mortality, primarily due to infections and graft failure. 2 The standard conditioning regimen for matched sibling HSCT for patients with SAA comprises cyclophosphamide (CY) at a dose of 200 mg/kg and equine antithymocyte globulin (ATG) (CY/ATG). This regimen promoted superior engraftment and survival rate compared with the historical regimen of CY alone. 3, 4 However, the use of high-dose CY has been associated with acute toxicity and severe morbidity including severe mucositis, hemorrhagic cystitis, veno-occlusive disease (VOD), invasive fungal infections, and transplant-related mortality. [5] [6] [7] A number of investigators have attempted to decrease the toxicity of CY in the cytoreduction in patients with SAA, by adding fludarabine (FLU) to the CY/ATG regimen, while decreasing the dose of CY and therefore maintaining the immunosuppressive degree of the cytoreduction. [8] [9] [10] [11] This regimen has been used successfully, particularly in alternative donor HSCT, often with the addition of low-dose total body irradiation (TBI). 12 In this series, we treated 4 pediatric patients with this approach of low-dose CY-ATG/plus FLU, followed by unmodified grafts from HLA-matched related donors. We describe their course and outcome.
PATIENTS AND METHODS

Patients
From January 2013 to 2014, 4 patients with idiopathic acquired severe or very severe aplastic anemia (vSAA) received HSCT from HLA-matched related donors at Memorial Sloan-Kettering Cancer Center. Approval of the Institutional Review Board/Privacy Board was obtained.
Cytoreductive Regimen and Transplantation
All 4 patients received FLU 30 mg/m 2 once daily intravenously (IV) on days −5, −4, −3, and −2; CY, at a total dose of 100 mg/kg-half the standard dose of 200 mg/ kg-with 50 mg/kg once daily IV on days −3 and −2; and equine ATG (ATGAM; Upjohn, Kalamazoo, MI) 30 mg/kg once daily IV on days −4, −3, and −2. Adequate hydration was provided during the conditioning chemotherapy and mesna was administered to prevent hemorrhagic cystitis. All patients received an unmodified bone marrow graft that was infused on day 0.
Graft Versus Host Disease (GvHD) Prophylaxis
A combination of a calcineurin inhibitor including cyclosporine (patient 2 and 3) or tacrolimus (patient 1 and 4) and standard dose methotrexate (MTX) was administered to all 4 patients. MTX was administered at a dose of 15 mg/m 2 IV on day +1, then 10 mg/m 2 IV on days +3, +6, and +11. All 4 patients received leucovorin rescue after MTX.
Supportive Care and Infectious Prophylaxis
Irradiated leukocyte-reduced red blood cell and platelet transfusions were administered to maintain hemoglobin above 7 g/dL and platelet count > 20×10 9 /L. Filgrastim was administered at 5 mcg/kg IV twice daily from day +1 until the absolute neutrophil count surpassed 2×10 9 /L for 3 consecutive days and was tapered thereafter. Intravenous low-dose heparin and ursodiol were used for VOD prophylaxis. Antimicrobial prophylaxis included sulfamethoxazole/trimethoprim or pentamidine, acyclovir, and micafungin. Broad-spectrum antibiotics were administered for the treatment of febrile neutropenia.
Assessment of Engraftment and Response
Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count ≥ 0.5×10 9 /L, and platelet recovery was defined as the day the platelet count was ≥ 20×10 9 /L without platelet transfusions. Engraftment and chimerism were evaluated by short tandem repeat polymorphism analysis and fluorescence in situ hybridization (FISH) technique in all 4 sexmismatched patients. The absolute lymphocyte counts, T cell, B cell, and natural killer (NK) cell populations were monitored. Acute and chronic GvHD were evaluated according to the 2014 National Institutes of Health Consensus. 13 
Toxicity
Regimen-related toxicity was graded according to Common Terminology Criteria for Adverse Events version 4.03. 14 
RESULTS
Patient Characteristics
There were 4 patients (2 males and 2 females), with a median age of 12 years (range, 6 to 20 y) at transplantation. Three patients were diagnosed with SAA and 1 patient with vSAA. The median cell counts of absolute neutrophil, platelet, and absolute reticulocyte at the time of diagnosis were 0.3×10 9 /L, 7×10 9 /L, and 24,000/μL, respectively. Patient 2 and patient 4 had been treated previously with filgrastim +/− eltrombopag without response. Three patients received <20 transfusions before HSCT, whereas patient 4 was heavily transfused with red blood cells and platelets. The median time from diagnosis to transplantation was 3 months (range, 0.7 to 4.9 mo). Specifically, patient 4 was diagnosed with vSAA and treated with immune suppression and eltrombopag, with no response. In addition, this patient had a prolonged pretransplant course that included a severe episode of sepsis with septic shock. Her transplant was postponed again because her sibling donor was found to have acute cytomegalovirus (CMV) infection with viremia and upper respiratory infection. Other patient characteristics are listed in Table 1 .
Engraftment and GvHD
The median total nucleated, CD34+, and CD3+ cell doses of the grafts were 2. /L occurred on days +21 and +23, respectively (range, 20 to 26). There was no evidence of early or late primary or secondary graft failure/rejection.
Three of the 4 patients were evaluated for lineagespecific donor chimerism, which was performed on peripheral blood leukocytes, myeloid, T cell, B cell, and NK cells. As shown in Figure 1 , patients 1, 2, and 3 had evidence of 92% to 100% donor cells in peripheral blood leukocytes, myeloid, B cell, and NK cells throughout their time after transplant. However, the T cells were 71% and 53% donor for patients 1 and 2 early after transplant, before increasing to 100% donor for both patients by 17 to 22 months after transplant. For patient 3, T cells were 100% donor throughout his time after transplant. Data on patient 4 were limited as this patient continued follow-up elsewhere, but showed evidence of 99% to 100% donor cells by FISH analysis from early to 2 years after transplant.
Patient 3, who had 100% donor T cells early after HSCT, developed grade 1 to 2 acute GvHD involving his liver and lower gastrointestinal tract starting on day +45 after HSCT, and responded to treatment with corticosteroids. At 5 months after HSCT, he developed chronic GvHD with lymphopenia and polyserositis manifestation, and pleural and pericardial effusion. These symptoms were successfully treated with methylprednisolone.
Toxicity, Complications, and Outcome
None of the patients developed grade 4 nonhematologic acute toxicity during the first 30 days after HSCT. Only patient 4 developed grade 1 mucositis, whereas the other patients had no mucositis at all. Nausea and vomiting were reported in all patients, but only 2 patients (1 and 2) required total parenteral nutrition support on the basis of clinical status. After completion of equine ATG, patients 1 and 3 developed a rash and fever without identified causative organism. Both patients were treated successfully with broad-spectrum antibiotics and supportive therapy. Patients 3 and 4 required narcotic medications for relief from bone pain (secondary to filgrastim-associated engraftment) and dysmenorrhea, respectively. Cyclosporine was substituted for tacrolimus on day +35 on patient 4 after the development of grade 3 thrombotic microangiopathy. Patients 1 and 4 had grade 3 metrorrhagia requiring medical treatment and transfusions accordingly. There was no episode of invasive fungal infections. None of the patients developed hemorrhagic cystitis or VOD (Table 2) .
One patient developed coagulase-negative staphylococcus bacteremia, which was reported at 1 month after HSCT and resolved after treatment with broad-spectrum antibiotics. There was no evidence of infections/reactivation of cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, adenovirus, BK polyomavirus, or Toxoplasma gondii in all 4 patients after transplantation.
With a median follow-up of 41.7 months (range, 34 tonormalization of peripheral blood counts within 36 days after transplant. The median number of red cell and platelet transfusions received during hospitalization were 2 (range, 1 to 5) and 7 (range, 4 to 19), respectively. The median duration of hospitalization was 27 days (range, 25 to 30 d). At 5 months after HSCT, patient 3 was admitted with tachypnea, tachycardia, and hypoxia. Work-up revealed evidence of polyserositis with pleural and pericardial effusion. This was assumed to be a rare manifestation of GvHD. The patient's symptoms resolved rapidly after treatment with systemic steroids. At 8 months after HSCT, this patient 
DISCUSSION
The preparative or conditioning regimen is an essential component in HSCT. The 3 aims of cytoreduction include immunoablation, myeloablation, and disease eradication. However, when HSCT is performed in patients with SAA, only immunoablation is required for engraftment.
Over the past decades, a number of investigators have attempted to change the conditioning regimen for the transplantation of patients with SAA to improve outcome and minimize toxicity. Since the 1970s, the major problem with matched related donor HSCT using CY alone at a dose of 200 mg/kg was a risk of graft rejection, which was as high as 30%. 15, 16 Storb et al 3, 17 demonstrated that the addition of ATG to high-dose CY promoted both excellent engraftment and long-term outcome, with a lower rate of GvHD. However, despite the satisfactory outcome, there remained significant rates of toxicity and infections including bacterial sepsis and fungal infections related to the standard dose of CY. 5 Similarly, in unrelated donor HSCT, the incidence of graft rejection remained significant as the CY/ATG regimen was found to be insufficient to sustain hematopoietic reconstitution in patients with SAA receiving grafts from unrelated donors. 18 Therefore, TBI was added to the CY/ ATG regimen to intensify the immunosuppression effect. Studies from the United States and Japan, using low-dose TBI, 2 to 10 Gy, CY 120 to 200 mg/kg plus ATG as a conditioning regimen, showed a low risk of rejection at 11%. Yet, the incidence of acute toxicity related to the TBI/CY/ ATG regimen was notably high, with an increase in lung and kidney injuries. 19, 20 To minimize the toxicity of conditioning regimens while maintaining the immunosuppressive effect, FLU-based conditioning regimens have been used recently in both matched related and unrelated donor HSCT for patients with idiopathic acquired SAA. Kang and colleagues reported the outcome of patients who received transplants from HLA-matched unrelated donors after a CY200/ATG plus FLU regimen. All patients developed both transaminitis and microscopic hematuria, and transplant-related mortality was high at 32%. 8, 11 Although the dose of CY was deescalated to 120 mg/kg in several studies, there was still evidence of VOD and invasive fungal infection in almost 10% of the recipients of matched related grafts. 10, 21 In our report, we treated patients with a lower dose of CY at 100 mg/kg, plus FLU in the conditioning regimen while maintaining the same dose of ATG. All patients engrafted without evidence of hemorrhagic cystitis, invasive fungal infection, or VOD. Patients developed some nausea and vomiting and transaminitis, but no grade 4 acute toxicities occurred during the first 30 days after transplant. These results show that using a lower dose of CY at 100 mg/ kg plus FLU in the HSCT conditioning regimen for pediatric patients with SAA had minimal toxicity.
Several investigators attempted to decrease the transplant toxicity of CY by decreasing the CY dose and adding FLU to the cytoreductive regimen. However, the risk of graft failure remained a concern, in particular, in multiple transfused patients with SAA, or those for whom there was a prolonged time interval between diagnosis and transplantation. 22, 23 The European Group for Blood and Marrow Transplant-SAA working party reported a high incidence of graft failure of 17% to 18% with the low dose of CY at 40 mg/kg, ATG plus FLU regimen in alternative donor HSCT. 9, 12 As expected, the rate of graft failures decreased significantly in recipients of matched sibling transplant using low-dose CY of 40 to 120 mg/kg, ATG plus FLU, reaching the 3% to 8% level. 10, 21, 24 In our report, the use of the cytoreductive regimen with 100 mg/kg of CY with ATG plus FLU led to sustained engraftment in all 4 patients, without evidence of graft failure/rejection. This report included 1 patient who had received multiple transfusions before HSCT and who proceeded to undergo transplantation 4 months after diagnosis.
Other investigators evaluated an alemtuzumab-based conditioning regimen together with low-dose CY. In a multicenter retrospective study, Marsh and colleagues treated 21 patients using FLU 30 mg/m 2 for 4 days, CY 300 mg/m 2 for 4 days, and a median total dose of 60 mg of alemtuzumab (range, 40 to 100 mg), followed by unmodified grafts from HLA-matched siblings. The overall survival at 2 years was 95%, but with a 9.5% incidence of graft failure and full donor chimerism only in 42% of patients. 25 In summary, in this small pilot study, the combination of low-dose CY, equine ATG, and the addition of FLU enabled durable engraftment, with tolerable regimen-related toxicity and comparable overall survival in pediatric patients receiving transplants from HLA-matched siblings. The comparison of the low-dose CY-FLU/ATG-based regimen with the standard regimen using CY200/ATG will need to be further evaluated in a large number of patients to enable a definitive assessment of the optimal conditioning regimen. 
